# A Study Evaluating the Safety and Efficacy of Second-Generation Tissue Engineered Vascular Grafts (TEVG2)

> **NIH NIH UH3** · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · 2021 · $539,634

## Abstract

PROJECT SUMMARY
We developed a tissue engineered vascular graft (TEVG) designed specifically for use in congenital heart
surgery. The TEVG is made by seeding autologous bone marrow-derived mononuclear cells onto a
biodegradable tubular scaffold. Once implanted the scaffold degrades and the TEVG transforms into a
neovessel that resembles a native blood vessel both in structure and function. Results of the first FDA-
approved clinical trial evaluating the use of the TEVG in children demonstrated that the TEVG is the first man-
made vascular conduit that grows making it uniquely suited for use in the surgical repair of complex congenital
heart defects, however; results of this study also demonstrated that incidence of stenosis was too high to
recommend routine use of this promising technology. We subsequently developed an improved, second-
generation TEVG that incorporates both rationally designed strategies for inhibiting the formation of TEVG
stenosis and process improvement measures for assembling the TEVG, in addition to newer less stringent
criteria for performing TEVG angioplasty. Herein we propose the next step in the development and translation
of the TEVG: a single-institution, prospective, single-armed, exploratory-confirmatory clinical trial designed to
evaluate the safety and efficacy of the second-generation TEVG in 24 patients over a 2-year period. In this
study, we will evaluate the short-term (2 year) safety and efficacy of a second-generation TEVG for use as an
extracardiac conduit in children with single ventricle cardiac anomalies undergoing modified Fontan surgery.
We will serially monitor all graft recipients over a 2-year time course using echocardiography and MRI. We
hypothesize that the second-generation TEVG will have a significantly lower incidence of critical stenosis
compared to the results of original TEVG in our previous FDA-approved pilot study. In addition, we hypothesize
that the TEVG will grow and transform over time into a highly compliant capacitance vessel. We will evaluate
the effect of graft compliance on flow, turbulence, and power loss across the TEVG in the Fontan circulation.
The development of a man-made vascular graft with growth capacity would enable the performance of
definitive reconstructive surgical procedures at an early age and mitigate the need for additional surgeries due
to somatic overgrowth (the process by which a child outgrows their implant), thereby improving outcomes in
patients with congenital heart disease.

## Key facts

- **NIH application ID:** 10026440
- **Project number:** 4UH3HL148693-02
- **Recipient organization:** RESEARCH INST NATIONWIDE CHILDREN'S HOSP
- **Principal Investigator:** christopher Kane breuer
- **Activity code:** UH3 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $539,634
- **Award type:** 4N
- **Project period:** 2019-09-11 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10026440

## Citation

> US National Institutes of Health, RePORTER application 10026440, A Study Evaluating the Safety and Efficacy of Second-Generation Tissue Engineered Vascular Grafts (TEVG2) (4UH3HL148693-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10026440. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*